Japan Tissue Engineering (7774) Stock Overview
Engages in the regenerative medicine business in Japan. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
7774 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Japan Tissue Engineering Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥695.00 |
| 52 Week High | JP¥749.00 |
| 52 Week Low | JP¥361.00 |
| Beta | 0.27 |
| 1 Month Change | 20.87% |
| 3 Month Change | 42.42% |
| 1 Year Change | 40.69% |
| 3 Year Change | 34.43% |
| 5 Year Change | -13.34% |
| Change since IPO | 76.40% |
Recent News & Updates
Optimistic Investors Push Japan Tissue Engineering Co., Ltd. (TSE:7774) Shares Up 27% But Growth Is Lacking
Dec 30
We're Not Worried About Japan Tissue Engineering's (TSE:7774) Cash Burn
Dec 29Recent updates
Optimistic Investors Push Japan Tissue Engineering Co., Ltd. (TSE:7774) Shares Up 27% But Growth Is Lacking
Dec 30We're Not Worried About Japan Tissue Engineering's (TSE:7774) Cash Burn
Dec 29Market Might Still Lack Some Conviction On Japan Tissue Engineering Co., Ltd. (TSE:7774) Even After 38% Share Price Boost
Apr 21Here's Why We're Not Too Worried About Japan Tissue Engineering's (TSE:7774) Cash Burn Situation
Apr 06Little Excitement Around Japan Tissue Engineering Co., Ltd.'s (TSE:7774) Revenues
Aug 01The Market Lifts Japan Tissue Engineering Co., Ltd. (TSE:7774) Shares 35% But It Can Do More
Mar 06We Think Japan Tissue Engineering (TYO:7774) Can Afford To Drive Business Growth
Feb 02Shareholder Returns
| 7774 | JP Biotechs | JP Market | |
|---|---|---|---|
| 7D | 12.5% | -3.0% | 1.0% |
| 1Y | 40.7% | 5.8% | 40.4% |
Return vs Industry: 7774 exceeded the JP Biotechs industry which returned 5.8% over the past year.
Return vs Market: 7774 matched the JP Market which returned 40.4% over the past year.
Price Volatility
| 7774 volatility | |
|---|---|
| 7774 Average Weekly Movement | 9.0% |
| Biotechs Industry Average Movement | 7.8% |
| Market Average Movement | 3.8% |
| 10% most volatile stocks in JP Market | 8.3% |
| 10% least volatile stocks in JP Market | 1.9% |
Stable Share Price: 7774's share price has been volatile over the past 3 months compared to the JP market.
Volatility Over Time: 7774's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of JP stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 204 | Kazuto Yamada | www.jpte.co.jp |
Japan Tissue Engineering Co., Ltd. engages in the regenerative medicine business in Japan. The company operates through Regenerative Medicine Product, Regenerative Medicine Contract, and Research and Development Support segments. It offers autologous cultured epidermis, cartilage, corneal epithelium, and oral mucosal epithelium to medical institutions for the purpose of medical treatment.
Japan Tissue Engineering Co., Ltd. Fundamentals Summary
| 7774 fundamental statistics | |
|---|---|
| Market cap | JP¥28.43b |
| Earnings (TTM) | -JP¥461.45m |
| Revenue (TTM) | JP¥2.26b |
Is 7774 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 7774 income statement (TTM) | |
|---|---|
| Revenue | JP¥2.26b |
| Cost of Revenue | JP¥912.11m |
| Gross Profit | JP¥1.35b |
| Other Expenses | JP¥1.81b |
| Earnings | -JP¥461.45m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
May 01, 2026
| Earnings per share (EPS) | -11.36 |
| Gross Margin | 59.62% |
| Net Profit Margin | -20.43% |
| Debt/Equity Ratio | 0% |
How did 7774 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/02/26 08:45 |
| End of Day Share Price | 2026/02/26 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Japan Tissue Engineering Co., Ltd. is covered by 4 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Hidemaru Yamaguchi | Citigroup Inc |
| Kiyokazu Yamazaki | Ichiyoshi Research Institute Inc. |
| Shigekazu Ishida | Marusan Securities Co. Ltd. |